Publications by authors named "H Nef"
We report a case of spontaneous coronary dissection (SCAD) in a 32-year-old pregnant patient during the seventh month of her second pregnancy. A 32-year-old pregnant woman in the 28th week of gestation was referred to our intensive care unit because of angina as well as elevated troponin levels. The initial electrocardiogram and transthoracic echocardiogram (TTE) were normal.
View Article and Find Full Text PDFAims: SPARCL1 was recently identified as a biomarker of right ventricular (RV) maladaptation in patients with pulmonary hypertension (PH), and N-terminal pro-brain natriuretic protein (NT-proBNP) is an established biomarker of RV failure in PH. The present study investigated whether NT-proBNP and SPARCL1 concentrations are associated with load-independent parameters of RV function and RV-to-pulmonary artery (RV-PA) coupling as measured using invasive pressure-volume (PV) loops in the RV.
Methods: SPARCL1 and NT-proBNP were measured in the plasma of patients with idiopathic pulmonary artery hypertension (IPAH, n = 73).
Introduction: Direct oral anticoagulant (DOAC) dose adjustment is based on age, renal function, and body weight. There is a paucity of data describing the factors associated with the prescription of inappropriate dosage and their impact on clinical outcomes among patients receiving transcatheter aortic valve implantation (TAVI).
Methods: In a single-center study, 432 patients who were on long-term DOAC therapy and underwent TAVI between 2015 and 2022 were included.
Background: Risk prediction in patients with severe, symptomatic aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) remains an unsolved issue. In addition to classical risk scoring systems, novel circulating biomarkers like mid-regional pro-adrenomedullin (MR-proADM) and growth differentiation factor 15 (GDF-15) may be of value in assessing risk.
Methods: Consecutive patients undergoing elective transfemoral TAVI were included in this prospective observational study.
Article Synopsis
- A hybrid strategy combining plug-based and suture-based vascular closure devices (VCDs) was studied to determine the effectiveness of ProGlide/AngioSeal versus ProGlide/FemoSeal after transcatheter aortic valve implantation (TAVI).
- A retrospective study of 608 patients revealed that the ProGlide/AngioSeal group had significantly higher rates of major bleeding and overall complications compared to the ProGlide/FemoSeal group.
- The findings suggest that using ProGlide/FemoSeal may lead to better outcomes within 30 days and that anterior wall calcification at the access site increases the risk of complications.